- Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer

Survival of NSCLC patients and Venn diagram summarizing the multimodal cohort A OS and PFS Kaplan-Meier survival curve (solid lines) for the whole NSCLC cohort (n = 311 for OS and n = 316 for PFS) with a 95% confidence interval (shaded areas). Patients are stratified with respect to their first-line therapy, either pembrolizumab alone or pembrolizumab + chemotherapy. Log-rank p-values are reported to characterize the separation of the survival curves. B OS and PFS Kaplan-Meier survival curves (solid lines) with 95% confidence interval (shaded areas) and log-rank p-values for the patients with available PD-L1 expression (n = 295 for OS and n = 300 for PFS). Patients are stratified with respect to their PD-L1 status (positive vs negative). C OS Kaplan-Meier survival curves (solid lines) with 95% confidence interval (shaded areas) and log-rank p-values for the 43 patients with available TMB and the 174 patients with available TILs status. For the TMB, patients are stratified with a threshold of 15 mutations per megabase (see Methods). For TILs, patients are stratified with respect to their positive vs negative TILs status. D Overview of the multimodal cohort with a Venn diagram. The four data modalities and their intersections are represented (i.e., PET/CT images, clinical data, pathological slides, and bulk RNA-seq profiles). Source data are provided as a Source Data file.

Go to figure page

Reference

Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer - Scientific Figure on ResearchGate. Available from: https://www.researchgate.net/figure/Survival-of-NSCLC-patients-and-Venn-diagram-summarizing-the-multimodal-cohort-A-OS-and_fig1_387951177 [accessed 24 Apr 2025]

Caption

Survival of NSCLC patients and Venn diagram summarizing the multimodal cohort
A OS and PFS Kaplan-Meier survival curve (solid lines) for the whole NSCLC cohort (n = 311 for OS and n = 316 for PFS) with a 95% confidence interval (shaded areas). Patients are stratified with respect to their first-line therapy, either pembrolizumab alone or pembrolizumab + chemotherapy. Log-rank p-values are reported to characterize the separation of the survival curves. B OS and PFS Kaplan-Meier survival curves (solid lines) with 95% confidence interval (shaded areas) and log-rank p-values for the patients with available PD-L1 expression (n = 295 for OS and n = 300 for PFS). Patients are stratified with respect to their PD-L1 status (positive vs negative). C OS Kaplan-Meier survival curves (solid lines) with 95% confidence interval (shaded areas) and log-rank p-values for the 43 patients with available TMB and the 174 patients with available TILs status. For the TMB, patients are stratified with a threshold of 15 mutations per megabase (see Methods). For TILs, patients are stratified with respect to their positive vs negative TILs status. D Overview of the multimodal cohort with a Venn diagram. The four data modalities and their intersections are represented (i.e., PET/CT images, clinical data, pathological slides, and bulk RNA-seq profiles). Source data are provided as a Source Data file.

Embed code

<a href="https://www.researchgate.net/figure/Survival-of-NSCLC-patients-and-Venn-diagram-summarizing-the-multimodal-cohort-A-OS-and_fig1_387951177"><img src="https://www.researchgate.net/publication/387951177/figure/fig1/AS:11431281303143990@1736740138228/Survival-of-NSCLC-patients-and-Venn-diagram-summarizing-the-multimodal-cohort-A-OS-and.png" alt="Survival of NSCLC patients and Venn diagram summarizing the multimodal cohort
A OS and PFS Kaplan-Meier survival curve (solid lines) for the whole NSCLC cohort (n = 311 for OS and n = 316 for PFS) with a 95% confidence interval (shaded areas). Patients are stratified with respect to their first-line therapy, either pembrolizumab alone or pembrolizumab + chemotherapy. Log-rank p-values are reported to characterize the separation of the survival curves. B OS and PFS Kaplan-Meier survival curves (solid lines) with 95% confidence interval (shaded areas) and log-rank p-values for the patients with available PD-L1 expression (n = 295 for OS and n = 300 for PFS). Patients are stratified with respect to their PD-L1 status (positive vs negative). C OS Kaplan-Meier survival curves (solid lines) with 95% confidence interval (shaded areas) and log-rank p-values for the 43 patients with available TMB and the 174 patients with available TILs status. For the TMB, patients are stratified with a threshold of 15 mutations per megabase (see Methods). For TILs, patients are stratified with respect to their positive vs negative TILs status. D Overview of the multimodal cohort with a Venn diagram. The four data modalities and their intersections are represented (i.e., PET/CT images, clinical data, pathological slides, and bulk RNA-seq profiles). Source data are provided as a Source Data file."/></a>